Phase 2a study of Aldeyra’s NS2 shows reduction in ocular itching, tearing in allergic conjunctivitis

NS2, an aldehyde-binding small molecule, reduced ocular itching and tearing in subjects with allergic conjunctivitis, according to phase 2a study results announced in a press release from Aldeyra Therapeutics.The study included 100 subjects with a 2-year history of allergic conjunctivitis to grass, tree or ragweed pollen. Subjects were randomized to receive topical ocular NS2 or a vehicle control.